Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1442 views | HTML 3516 views | ?
Kun Dai1, Fengxia Qin1, Huikun Zhang1, Xiaoli Liu2, Caixia Guo3, Ming Zhang4, Feng Gu1, Li Fu1, Yongjie Ma2
1Department of Breast Cancer Pathology and Research Laboratory, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
2Department of Tumor Cell Biology, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China
3CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
4Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA, U.S.A
Yongjie Ma, e-mail: [email protected]
Feng Gu, e-mail: [email protected]
Li Fu, e-mail: [email protected]
Keywords: BMPRIB, breast cancer, bone metastasis, TE chemotherapy, prognosis
Received: September 10, 2015 Accepted: November 26, 2015 Published: December 14, 2015
Bone morphogenetic protein receptor type IB (BMPRIB) is one osteogenesis factor, which function in breast cancer has been rarely explored until recently. In the clinical study presented here, involving a cohort of 368 invasive ductal carcinoma (IDC) patients, we identified that patients with low expression of BMPRIB exhibited poor prognosis, especially in the luminal B subtype. We also provided the first piece of evidence that low level of BMPRIB was a promoting factor for breast cancer patients to develop bone metastasis, but not lung, liver or brain. The first of its kind, we reported that patients with high expression of BMPRIB exhibited favorable prognosis by a retrospective analysis consisting of 168 patients treated with TE (taxane and anthracycline) regimens. And the patients with high expression of BMPRIB were more sensitive to TE regimens in the detection of 32 paired pre-neoadjuvant and post-neoadjuvant specimens. Overall, our study concluded that low expression of BMPRIB indicated poor prognosis of breast cancer and was insensitive to taxane-anthracycline chemotherapy. Our findings also lay a foundation to help clinicians improve identification of patients for TE regimens by BMPRIB in the era of precision medicine.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.